How many MSM in Europe could benefit from PrEP -a 9 billion Euro question?
Union who are eligible for PrEP according to the CDC are calculated by applying the eligibility criteria to the estimated MSM populations in each country. 9 As national response rates across the 38 included countries differ substantially, country medians are reported. CDC guidelines 7 recommend PrEP for MSM who are adult, HIV negative, have had a male sex partner in the past six months, are not in a mutually monogamous relationship with a recently tested HIV-negative man and at least one of the following:
. Any anal intercourse without condoms (receptive or insertive) in the past six months. . Any STI diagnosed or reported in past six months.
. Is in an ongoing sexual relationship with an HIVpositive male partner.
Given the overlap of the three indications, we prioritised them in the order above. As shown in Figure 1 , 4.3% of EMIS respondents (median of 38 countries) reported having been diagnosed with HIV; 11.8% reported a steady partner of HIV-negative status and no other sexual partners in the last 12 months -these were classified as monogamous. According to CDC recommendations, 39.0% would qualify for PrEP because of unprotected anal intercourse in the past six months outside a monogamous relationship. An additional 1.0% would qualify solely because of reporting an STI in the past six months and an additional 0.7% solely based on reporting having a steady partner with diagnosed HIV. A total of 40.7% thus met the CDC guidelines for PrEP.
There are a number of important limitations to our estimates. EMIS was not a representative sample of MSM. Various lines of evidence suggest that EMIS sampled a somewhat higher-risk group of MSM. 9, 10 This would result in our estimates being too high. Another determinant of exaggerated estimates is the fact that the CDC guideline does not consider partners' viral load -57.5% of HIV-diagnosed EMIS respondents reported an undetectable viral load, and could be regarded as non-infectious. 11 Other factors may result in our estimates being too low. One such factor is that a proportion of men who reported a steady partner of HIV-negative status and no other sexual partners in the last 12 months reported a diagnosis of an STI in the previous six months. A reasonable case could be made that they be regarded as eligible for PrEP. Further studies are required to best define the risk profile that would obtain the optimal benefit from PrEP.
The 38 countries in EMIS have an estimated population of 5 million MSM aged 18 to 64. 9 If our measures were representative, then approximately 2 million in the 38 EMIS countries or 1.4 million in the European Union (EU) would qualify for PrEP. The retail price of a year's supply of standard PrEP (Truvada Õ ) in the EU is 6500 E or 8100 US$. At this price, daily doses would cost 9.1 billion E per year for the 1.4 million men in the EU, excluding the other costs associated with PrEP implementation, which would require substantial health service infrastructure and staffing, and community education for MSM.
Studies are required to establish the cost effectiveness of various PrEP targeting strategies in the EU. A systematic review of five cost effectiveness studies in MSM in the USA and Peru found that PrEP's cost effectiveness varied widely according to a number of factors including the degree of targeting and the cost of the emtricitabine/tenofovir. 12 In studies with little targeting PrEP cost US$ 298,000-570,000/quality adjusted life year gained. 13, 14 PrEP was considerably more cost effective or even cost saving in studies that targeted higher-risk MSM. 15 The price of emtricitabine/tenofovir was a key determinant of cost effectiveness. 12 In Peru, for example, PrEP cost US$ 403-1779 per disability life year averted. This lower cost was largely due to the lower cost of emtricitabine/tenofovir in Peru. 12 Cost effectiveness studies should not, however, limit themselves to the US$ 8100 annual cost for emtricitabine/tenofovir. Generic lamivudine/tenofovir is available at US$ 57 per year 16 and the current European patent for Truvada Õ will expire in 2018. 17 Various strategies could be used to reduce the price of the drugs used for PrEP.
More debate is required as to the optimal pricing of PrEP and who should pay for it. The provision of PrEP is not the only way to prevent HIV. This is quite different from the way that ART is the predominant way to prevent death from AIDS. PrEP also has no effect on reducing the transmission of other STIs. Although the provision of PrEP has not been found to lead to an increase in risk behaviours, there are three important caveats to this. 3 Firstly, this was in the setting of trials that could provide considerable resources for counseling. Secondly, this was evaluated at an individual level only. At a population level it is likely that the provision of ART as therapy contributed to risk compensation in MSM as seen in certain countries. 18, 19 PrEP could have a similar effect. 18 Thirdly, the PrEP used in all the trials thus far was free to participants. The results of the IPERGAY study suggest that intermittent PrEP (before and after sex) is as effective (and cheaper) than uninterrupted PrEP. 4 If people use PrEP in this way, it is possible that the number of sex acts with casual partners could vary inversely with PrEP prices. This raises the possibility that there may be an optimal price for PrEP for a particular population. Determining if this is the case would require not only empirical studies but also dealing with difficult ethical questions and, crucially, negotiations with affected communities.
We could create considerable synergy and re-energise HIV prevention efforts if PrEP was made more accessible, but done so in a way that promotes safer sexual practices.
